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What is real-world evidence?
“...the clinical evidence regarding the usage 
and potential beneﬁts or risks of a medical 
product derived from analysis of real-world 
data…”
Corrigan-Curay, Sacks, Woodcock. Real-World Evidence and Real-World 
Data for Evaluating Drug Safety and Effectiveness. JAMA 2018
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What are real-world data?
Real-world data are the data relating to patient health status and/or the delivery of 
healthcare routinely collected from a variety of sources 
Electronic health records
Patient-generated data 
(e.g. in-home settings)
Claims & billing activities Product & disease registries
Data gathered from other sources 
that can inform on health stats 
(e.g. mobile devices)
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RWE isn’t new
“Course of the disease is predictable, and the effect of the drug is 
substantial” -- Corrigan-Curay, Sacks, Woodcock. JAMA 2018
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We used to think there was only one situation when a 
randomized controlled clinical trial wasn’t appropriate
Parachute use to prevent 
death and major trauma 
related to gravitational 
challenge: systematic review of 
randomized controlled trials
(BMJ 2003;327:1459-1461) 
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What has changed?
● Demand
● Supply
● Policy
© Flatiron Health 2019
The demand for evidence in oncology is at 
unprecedented levels
Exploding 
R&D 
Pipelines
Combination 
therapies
Precision 
Medicine
Value-based 
care
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Limitations of Prospective Randomized Clinical Trials
 Not representative
 Lengthy
 Costly
 Not feasible with rare clinical scenarios
 Randomization may be ethically-challenging
 Sponsors may not wish to compare 2 standard 
treatments
Real-world data can provide complementary 
evidence
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The opportunity for RWE
But…..how do we overcome the limitations of 
these real-world data?
Almost every cancer 
patient’s story lives in an 
electronic health record
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FDA recently drafted key documents on RWE to drive 
forward the 21st Century Cures mandate
The Framework includes considerations of the following:
(1) Whether the RWD are ﬁt for use. 
(2) Whether the trial or study design used to generate RWE can 
provide adequate scientiﬁc evidence to answer or help answer 
the regulatory question
(3) Whether the study conduct meets FDA regulatory 
requirements (e.g., for study monitoring and data collection) 
Series of draft guidances being 
released by the FDA  
10
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RWE can be applied to various use cases to support 
regulatory submissions
To compare or provide 
context for a treatment arm 
in single arm trial
To provide disease 
context
To characterize 
unmet need
New Filing Label Update or Expansion Post-Marketing Studies
Regulatory Objective
Use Cases for RWE Aligned to Objective
To evaluate safety and/or 
eﬀectiveness  
To modify indication 
(e.g., dose)
11
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Demand
Supply
Policy
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EHR Hospital
Lab
Getting from 
DATA to 
EVIDENCE
Demographics
Diagnosis Visits
Labs Therapies
Discharge Notes
Pathology
Physician Notes
Radiology 
Structured and Unstructured 
Data in the EHR
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Structured data requires normalization and harmonization
Certain structured data elements may be 
coded and collected in multiple ways in the 
EHR across practices
2220 Blood Serum Albumin                                                             g/dL
QD25001600 ALBUMIN/GLOBULIN RATIO  QD (calc)
QD25001400 ALBUMIN  QD g/dL
QD50058600 ALBUMIN %                             
QD50055700 ALBUMIN g/dL
CL3215104 Albumin % (EPR) %                             
LC001081 ALBUMIN, SERUM (001081) g/dL
LC003718 Albumin, U %                             
LC001488 Albumin g/dL
LC133751 Albumin, U %                             
CL3215162 Albumin%, Urine %                             
CL3215160 Albumin, Urine mg/24hr
3234 ALBUMIN SS g/dL
LC133686 Albumin, U %                             
QD50060710 MICROALBUMIN mg/dL                         
QD50061100 MICROALBUMIN/CREATININE RATIO, 
RANDOM URINE
mcg/mg 
creat
QD85991610 ALBUMIN relative %
50058600 ALBUMIN UPEP RAND %                             
CL3210074 ALBUMIN LEVEL g/dL
QD86008211 ALBUMIN/GLOBULIN RATIO (calc)
LC149520 Albumin g/dL
QD45069600 PREALBUMIN mg/dL                         
QD900415245 ALBUMIN, SERUM mg/dl                         
Example: Albumin
1751-7
Albumin 
[Mass/volume] 
in Serum or Plasma
g/dL
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Unstructured documents contain essential information
Example: Unstructured Data Points
• EGFR testing status
• EGFR test result
• Speciﬁc mutation type (e.g., T790M)
• Date sample was collected
• Date sample was received in lab
• Date result was provided to physician
• Type of test (e.g., NGS)
• Type of sample (e.g., tissue)
• Sample collection site
… for every EGFR test the patient receives
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ML will empower humans, not replace them
ML is great at 
● classiﬁcation
● recommendation
● ranking
● pattern-recognition
Humans are great at 
● synthesizing information
● applying domain-speciﬁc 
knowledge
● adapting to novel information
Humans will always be necessary for
● Generating training data
● Evaluating the performance of ML models
© Flatiron Health 2019
Expert abstractors
A network of abstractors 
comprised of oncology nurses, 
certiﬁed tumor registrars, and 
oncology clinical research 
professionals.
Flatiron Technology
Software helps trained human 
abstractors eﬃciently organize 
and review unstructured 
documents to capture key data 
elements in predetermined 
forms.
The Process: Technology Enabled Abstraction
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A Special Challenge for RWE in Cancer Research:
Deﬁning Endpoints
● The gold-standard = survival
● Surrogate endpoints for clinical beneﬁt are commonly used in clinical trials
○ Tumor response and tumor progression - based on measurements on 
CT scans (RECIST Criteria)
● “Real-world Endpoints” are challenging
○ Survival dates often missing
○ CT scans not routinely available
○ Scan selection is variable
○ Scan timing is variable
○ Radiology report measurements are inconsistent and often qualitative
○ Direct comparisons to CT scans may introduce bias
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Mortality is often missing from the EHR
This requires linking of EHR data with external sources
COMMERCIAL SSDIEHR
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Sensitivity and speciﬁcity of mortality endpoint optimized by 
merging data sources
Data shown for advNSCLC
Curtis M et al. Development and Validation of a High Quality Composite Real-World Mortality Endpoint. 
Health Services Research 14 May 2018 doi:10.1111/1475-6773.12872
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Three-pronged framework for assessment of 
validity of real-world endpoints
  
Develop an 
approach with
face validity
1. Oncologist agreement with deﬁnition & 
approach
2. Regulatory stakeholder alignment with 
deﬁnition & approach
Ensure that the 
approach has 
internal validity
3. Completeness of collected data
4. Inter-rater agreement on datapoint for 
duplicate abstracted patients
Assess the 
external validity of 
the data point
5. Likelihood of predicting downstream events 
(e.g., treatment change, OS)
6. Comparison to other endpoints (e.g., OS, 
RECIST) or external data sources (if available)
Flatiron approach to 
rwResponse and 
rwProgression:
Based upon oncologist 
documentation in the 
context of supporting data
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To improve lives by learning from the 
experience of every cancer patient 
OUR MISSION
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To improve lives by learning from the 
experience of every cancer patient 
OUR MISSION
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Cohort Demographics
as of May 2019
Histology Smoking Status
Patients in cohort: 54,883 (Community: 50,132  | Academic: 4,751)
History of 
smoking
No history of 
smoking
Unknown / not 
documented
Not otherwise 
speciﬁed
Non-squamous 
cell carcinoma
Squamous cell 
carcinoma
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PDL1 Biomarker Testing and FDA Approvals of Immune 
Checkpoint inhibitors in NSCLC
PDL1 Testing Rate Among Actively Treated Patients
Opdivo for recurrent 
squamous cell [Mar 2015]
Keytruda for recurrent PDL1+ 
NSCLC [Oct 2015]
Keytruda for ﬁrst line PDL1+ 
NSCLC [Oct 2016]
Keytruda plus chemo for ﬁrst line NSCLC, 
regardless of PDL1 [May 2017]
Keytruda for any MSI-High 
tumor [May 2017]
Opdivo for recurrent NSCLC 
[Oct 2015]
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Patient Share by Therapy Class — PD1/PDL1
All Lines
0%
Q3 2014
58%
Q2 2019
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Understanding Uptake of New Biomarkers and Treatments
Commercial 
Applications
Regulatory 
Applications
How is Flatiron RWD being used?
Cost Eﬀectiveness Modeling
Discovery and Validation of New Predictive Biomarkers
Comparative Eﬀectiveness of Standard Treatments
Research and Clinical 
Applications
Quality Measurement / Impact of Healthcare Policy
Submission of Real-World Outcomes for Regulatory D cisions
Risk Modeling
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RWE Considerations
Data Quality
     Completeness
     Representativeness
     Clinical Depth
     Longitudinal Follow-Up
     Timeliness/Recency
     Clear Provenance
     Measurement Reliability/Validity
Analytic Rigor
Pre-Speciﬁed Analysis Plan
Confounders
Bias
Cohort Selection
Adapted from: Berger et al. on behalf of ISPOR‐ISPE 
Special Task Force on Real‐World Evidence in Health 
Care Decision Making. Value in Health, 2017;  Miksad and 
Abernethy, Clin Pharmacol Ther, 2018.
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Case study: Does genomic testing improve survival for lung 
cancer patients?
Presley et al. JAMA 2018
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TMB as Predictive Biomarker in NSCLC
Singal, Miller,  Agarwala, et al. JAMA. 2019;321(14):1391-1399.
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Case Study: Disparities Research
O’Connor JM, et al. JAMA Oncol, 2018
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Evaluating 
real-world 
outcomes of 
NSCLC patients 
treated with PD-1 
inhibitors
FDA + FLATIRON Overall survival of PD-1 inhibitor treated patients
based on lines of therapy
Khozin et al. The 
Oncologist, 2019.
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64%
Median age in clinical trials = 62; <8% were 75 or over
Khozin S. et al. The Oncologist. Jan 9, 2018;22:1–9 
Real-world patients are diﬀerent than trial patients
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Can RWE help provide context for clinical trials, 
and assist in their design?
● Assessing generalizability: did the patients in the 
clinical trial look like those treated in “the real world”?
● Assessing relevance: did the control arm actually 
reﬂect the current standard of care?
SOC Relevance 
score = C/A 
Generalizability 
score = C/B 
BA
C
Eligible for trial
Received 
treatment 
consistent with 
trial’s control arm 
Standard of Care (SOC) Relevance and Generalizability
Bennett et al. ASCO Annual 
Meeting 2019
Urothelial
Multiple myeloma
Renal cell carcinoma
Non-small cell lung cancer
Breast cancer
Median (range) of scores:
● Generalizability: 63% 
(35%-88%)
● SOC relevance: 37% 
(15%-74%)
Relevance and Generalizability of 
Randomized Clinical Trials
Bennett et al. ASCO Annual 
Meeting 2019
Affordable Care Act Medicaid 
Expansion Impact on Racial Disparities 
in Timely Cancer Treatment
Adamson et al. ASCO 2019 Annual Meeting
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Methods
Study sample: Adults 18-64 years, 
diagnosed with advanced cancer 
(N=30,386)
Outcome: timely treatment = systemic 
cancer treatment initiated w/in 30 days of 
diagnosis
Study design: Compares experience of 
black relative to white patients
• Diagnosed in states after Medicaid 
expansion compared to pre-expansion 
or in states not expanding by 2019.
Diﬀerence-in-Diﬀerences
Adamson et al. ASCO 2019 Annual Meeting
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Results: Demographics
Patient Population (N = 30,386)
Not Expanded
(n = 18,678)
Expanded
(n = 11,708)
Median Age, Years
  [IQR]
57.0
[51.0-61.0]
57.0
[52.0-61.0]
Male, % 47.1 48.4
Race: White, % 73.3 70.3
Race: Black, % 14.6 8.7
Adamson et al. ASCO 2019 Annual Meeting
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Medicaid expansion associated with reduced racial 
disparities in timely treatment
Adamson et al. ASCO 2019 Annual Meeting
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Medicaid expansion associated with reduced racial 
disparities in timely treatment
Adamson et al. ASCO 2019 Annual Meeting
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Medicaid expansion associated with reduced racial 
disparities in timely treatment
Adamson et al. ASCO 2019 Annual Meeting
Impact of Oncology Care Model Reporting 
Requirements on Quality of Care
• The Oncology Care Model (OCM) is a voluntary Center for Medicare 
and Medicaid Innovation alternative payment model pilot program
• Requires reporting of certain quality metrics, eg. frequency of 
biomarker testing in patients with lung cancer
• We conducted a natural experiment to assess the effect of an OCM 
reporting policy on quality of care for patients with advanced non-small 
cell lung cancer.
• Quality metric: Rates of biomarker testing and of biomarker- 
directed therapy
• Castellanos et al. ASCO Annual Meeting 2019
Result: Diﬀerence-in-Diﬀerences Model Showed no 
Changes in Downstream Care Associated to OCM
OR = 1.09 (95% CI: 0.88 - 1.34); P = 0.45 
     Non OCM (n = 5897)           OCM (n = 8151)•                         •      Biomarker Testing 
Rates
Castellanos et al. ASCO Annual Meeting 2019
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Quality Measurement: Trends in EOL Treatment
in Urothelial Cancer
Parikh R., et al. Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the 
End of Life: Insights from Real-World Practice.  The Oncologist. 10.1634/2019-0039. 
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Real-World Data for Quality Improvement
● Real-time
● Site, clinical team, 
physician-level metrics
Kraut et al. J Oncol Practice, 20 9
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A look to the future - a new paradigm for RWE in 
drug development
Retrospective 
RWE
Prospective 
Evidence 
Generation
Consent
The Continuum of RWE
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A look to the future - a new paradigm for RWE in 
drug development
Retrospective 
RWE
Prospective 
Evidence 
Generation
Consent
The Continuum of RWE ● Use technology to bridge the gap 
between retrospective RWE and 
prospective evidence generation
● Apply to novel use cases 
including:
○ Biomarker validation
○ Post-marketing 
○ Pharmacovigilance
○ Expanded indications
○ Real-world external controls
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